{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:07:06Z","timestamp":1770224826523,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ISCIII\/PI14-01140\/Cofinanced FEDER"],"award-info":[{"award-number":["ISCIII\/PI14-01140\/Cofinanced FEDER"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["ED431B 2016\/022"],"award-info":[{"award-number":["ED431B 2016\/022"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["IN607A2019\/02"],"award-info":[{"award-number":["IN607A2019\/02"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00109-021-02129-4","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T10:03:34Z","timestamp":1631786614000},"page":"1741-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value"],"prefix":"10.1007","volume":"99","author":[{"given":"Cristina","family":"Almengl\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinela","family":"Couselo-Seijas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa M.","family":"Agra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Varela-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Garc\u00eda-Acu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Gonz\u00e1lez-Peteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Eiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2381-8425","authenticated-orcid":false,"given":"Ezequiel","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2129_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1042\/CS20171550","volume":"133","author":"AM South","year":"2019","unstructured":"South AM, Shaltout HA, Washburn LK, Hendricks AS, Diz DI, Chappell MC (2019) Fetal programming and the angiotensin-(1\u20137) axis: a review of the experimental and clinical data. Clin Sci (Lond) 133:55\u201374. https:\/\/doi.org\/10.1042\/CS20171550","journal-title":"Clin Sci (Lond)"},{"key":"2129_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ndt\/gfw206","volume":"32","author":"B Trojanowicz","year":"2017","unstructured":"Trojanowicz B, Ulrich C, Kohler F, Bode V, Seibert E, Fiedler R, Girndt M (2017) Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease. Nephrol Dial Transplant 32:287\u2013298. https:\/\/doi.org\/10.1093\/ndt\/gfw206","journal-title":"Nephrol Dial Transplant"},{"key":"2129_CR3","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.res.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139. Circ Res 87:E1-9. https:\/\/doi.org\/10.1161\/01.res.87.5.e1","journal-title":"Circ Res"},{"key":"2129_CR4","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","volume":"41","author":"IE Sama","year":"2020","unstructured":"Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, Rienstra M, Friedrich AW, Samani NJ, Ng LL, Dickstein K, Lang CC, Filippatos G, Anker SD, Ponikowski P, Metra M, van Veldhuisen DJ, Voors AA (2020) Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J 41:1810\u20131817. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa373","journal-title":"Eur Heart J"},{"key":"2129_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jacc.2008.02.088","volume":"52","author":"S Epelman","year":"2008","unstructured":"Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S (2008) Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52:750\u2013754. https:\/\/doi.org\/10.1016\/j.jacc.2008.02.088","journal-title":"J Am Coll Cardiol"},{"key":"2129_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cardfail.2009.01.014","volume":"15","author":"S Epelman","year":"2009","unstructured":"Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, Tang WH (2009) Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15:565\u2013571. https:\/\/doi.org\/10.1016\/j.cardfail.2009.01.014","journal-title":"J Card Fail"},{"key":"2129_CR7","doi-asserted-by":"publisher","first-page":"e0198144","DOI":"10.1371\/journal.pone.0198144","volume":"13","author":"J Ramchand","year":"2018","unstructured":"Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM (2018) Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS ONE 13:e0198144. https:\/\/doi.org\/10.1371\/journal.pone.0198144","journal-title":"PLoS ONE"},{"key":"2129_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/europace\/euw246","volume":"19","author":"TE Walters","year":"2017","unstructured":"Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM (2017) Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace 19:1280\u20131287. https:\/\/doi.org\/10.1093\/europace\/euw246","journal-title":"Europace"},{"key":"2129_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jcmg.2019.09.005","volume":"13","author":"J Ramchand","year":"2020","unstructured":"Ramchand J, Patel SK, Kearney LG, Matalanis G, Farouque O, Srivastava PM, Burrell LM (2020) Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc Imaging 13:655\u2013664. https:\/\/doi.org\/10.1016\/j.jcmg.2019.09.005","journal-title":"JACC Cardiovasc Imaging"},{"key":"2129_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111:2605\u20132610. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.510461","journal-title":"Circulation"},{"key":"2129_CR11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(20)31964-4","volume":"396","author":"S Narula","year":"2020","unstructured":"Narula S, Yusuf S, Chong M, Ramasundarahettige C, Rangarajan S, Bangdiwala SI, van Eikels M, Leineweber K, Wu A, Pigeyre M, Pare G (2020) Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet 396:968\u2013976. https:\/\/doi.org\/10.1016\/S0140-6736(20)31964-4","journal-title":"Lancet"},{"key":"2129_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.2353\/ajpath.2008.070762","volume":"172","author":"V Koka","year":"2008","unstructured":"Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY (2008) Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK\/p38 MAP kinase pathway. Am J Pathol 172:1174\u20131183. https:\/\/doi.org\/10.2353\/ajpath.2008.070762","journal-title":"Am J Pathol"},{"key":"2129_CR13","first-page":"625","volume":"35","author":"XS Hu","year":"2007","unstructured":"Hu XS, Xie XD, Wang XX, Zeng CL, Ni YM, Yu GW, Chen JZ (2007) Effects of angiotensin converting enzyme inhibitor on the expression of angiotensin converting enzyme 2 in atrium of patients with atrial fibrillation. Zhonghua Xin Xue Guan Bing Za Zhi 35:625\u2013628","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"2129_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1741-7015-2-19","volume":"2","author":"AB Goulter","year":"2004","unstructured":"Goulter AB, Goddard MJ, Allen JC, Clark KL (2004) ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2:19. https:\/\/doi.org\/10.1186\/1741-7015-2-19","journal-title":"BMC Med"},{"key":"2129_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2020","author":"S Lebek","year":"2020","unstructured":"Lebek S, Tafelmeier M, Messmann R, Provaznik Z, Schmid C, Maier LS, Birner C, Arzt M, Wagner S (2020) ACE inhibitor\/angiotensin II receptor blocker treatment and hemodynamic factors are associated with increased cardiac mRNA expression of ACE2 in patients with cardiovascular disease. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.2020","journal-title":"Eur J Heart Fail"},{"key":"2129_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/eurheartj\/ehi256","volume":"26","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM (2005) Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26:1141\u20131143. https:\/\/doi.org\/10.1093\/eurheartj\/ehi256","journal-title":"Eur Heart J"},{"key":"2129_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/db09-1218","volume":"59","author":"GY Oudit","year":"2010","unstructured":"Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59:529\u2013538. https:\/\/doi.org\/10.2337\/db09-1218","journal-title":"Diabetes"},{"key":"2129_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ijcard.2009.11.057","volume":"145","author":"M Ohtsuki","year":"2010","unstructured":"Ohtsuki M, Morimoto SI, Izawa H, Ismail TF, Ishibashi-Ueda H, Kato Y, Horii T, Isomura T, Suma H, Nomura M, Hishida H, Kurahashi H, Ozaki Y (2010) Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int J Cardiol 145:333\u2013334. https:\/\/doi.org\/10.1016\/j.ijcard.2009.11.057","journal-title":"Int J Cardiol"},{"key":"2129_CR19","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1161\/01.CIR.0000094734.67990.99","volume":"108","author":"LS Zisman","year":"2003","unstructured":"Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC (2003) Increased angiotensin-(1\u20137)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 108:1707\u20131712. https:\/\/doi.org\/10.1161\/01.CIR.0000094734.67990.99","journal-title":"Circulation"},{"key":"2129_CR20","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1007\/s00018-021-03779-w","volume":"78","author":"T Kawai","year":"2021","unstructured":"Kawai T, Elliott KJ, Scalia R, Eguchi S (2021) Contribution of ADAM17 and related ADAMs in cardiovascular diseases. Cell Mol Life Sci 78:4161\u20134187. https:\/\/doi.org\/10.1007\/s00018-021-03779-w","journal-title":"Cell Mol Life Sci"},{"key":"2129_CR21","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1530\/JOE-20-0260","volume":"247","author":"MJ Young","year":"2020","unstructured":"Young MJ, Clyne CD, Chapman KE (2020) Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. J Endocrinol 247:R45\u2013R62. https:\/\/doi.org\/10.1530\/JOE-20-0260","journal-title":"J Endocrinol"},{"key":"2129_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118075","volume":"257","author":"T Behl","year":"2020","unstructured":"Behl T, Kaur I, Bungau S, Kumar A, Uddin MS, Kumar C, Pal G, Sahil SK, Zengin G, Arora S (2020) The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. Life Sci 257:118075. https:\/\/doi.org\/10.1016\/j.lfs.2020.118075","journal-title":"Life Sci"},{"key":"2129_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/CS20200482","volume":"135","author":"RK Sharma","year":"2021","unstructured":"Sharma RK, Li J, Krishnan S, Richards EM, Raizada MK, Mohandas R (2021) Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases. Clin Sci (Lond) 135:1\u201317. https:\/\/doi.org\/10.1042\/CS20200482","journal-title":"Clin Sci (Lond)"},{"key":"2129_CR24","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","volume":"75","author":"AHJ Danser","year":"2020","unstructured":"Danser AHJ, Epstein M, Batlle D (2020) Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 75:1382\u20131385. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15082","journal-title":"Hypertension"},{"key":"2129_CR25","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","volume":"114","author":"VJ Dzau","year":"2006","unstructured":"Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W (2006) The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 114:2850\u20132870. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.655688","journal-title":"Circulation"},{"key":"2129_CR26","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1161\/CIRCULATIONAHA.106.655761","volume":"114","author":"VJ Dzau","year":"2006","unstructured":"Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W (2006) The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 114:2871\u20132891. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.655761","journal-title":"Circulation"},{"key":"2129_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/eurjhf\/hfq117","volume":"12","author":"S Raposeiras-Roubin","year":"2010","unstructured":"Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, Moure-Gonzalez M, Seoane-Blanco A, Varela-Roman A, Alvarez E, Gonzalez-Juanatey JR (2010) Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE. Eur J Heart Fail 12:1092\u20131100. https:\/\/doi.org\/10.1093\/eurjhf\/hfq117","journal-title":"Eur J Heart Fail"},{"key":"2129_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074302","volume":"8","author":"S Raposeiras-Roubin","year":"2013","unstructured":"Raposeiras-Roubin S, Rodino-Janeiro BK, Paradela-Dobarro B, Grigorian-Shamagian L, Garcia-Acuna JM, Aguiar-Souto P, Jacquet-Hervet M, Reino-Maceiras MV, Gonzalez-Juanatey JR, Alvarez E (2013) Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome. PLoS ONE 8:e74302. https:\/\/doi.org\/10.1371\/journal.pone.0074302","journal-title":"PLoS ONE"},{"key":"2129_CR29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.numecd.2019.06.014","volume":"29","author":"B Paradela-Dobarro","year":"2019","unstructured":"Paradela-Dobarro B, Agra RM, \u00c3lvarez L, Varela-Rom\u00e1n A, Garc\u00eda-Acu\u00f1a JM, Gonz\u00e1lez-Juanatey JR, \u00c1lvarez E, Garc\u00eda-Seara FJ (2019) The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings. Nutr Metab Cardiovasc Dis 29:1050\u20131060. https:\/\/doi.org\/10.1016\/j.numecd.2019.06.014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2129_CR30","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129\u20132200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"2129_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/JME-15-0031","volume":"56","author":"B Paradela-Dobarro","year":"2016","unstructured":"Paradela-Dobarro B, Rodi\u00f1o-Janeiro BK, Alonso J, Raposeiras-Roub\u00edn S, Gonz\u00e1lez-Peteiro M, Gonz\u00e1lez-Juanatey JR, \u00c1lvarez E (2016) Key structural and functional differences between early and advanced glycation products. J Mol Endocrinol 56:23\u201337. https:\/\/doi.org\/10.1530\/JME-15-0031","journal-title":"J Mol Endocrinol"},{"key":"2129_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY (2014) Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol 66:167\u2013176. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.11.017","journal-title":"J Mol Cell Cardiol"},{"key":"2129_CR33","doi-asserted-by":"publisher","first-page":"e61695","DOI":"10.1371\/journal.pone.0061695","volume":"8","author":"JT Ortiz-P\u00e9rez","year":"2013","unstructured":"Ortiz-P\u00e9rez JT, Riera M, Bosch X, De Caralt TM, Perea RJ, Pascual J, Soler MJ (2013) Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS ONE 8:e61695. https:\/\/doi.org\/10.1371\/journal.pone.0061695","journal-title":"PLoS ONE"},{"key":"2129_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271\u2013280. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"2129_CR35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1128\/JVI.02202-13","volume":"88","author":"A Heurich","year":"2014","unstructured":"Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 88:1293\u20131307. https:\/\/doi.org\/10.1128\/JVI.02202-13","journal-title":"J Virol"},{"key":"2129_CR36","doi-asserted-by":"publisher","first-page":"e040644","DOI":"10.1136\/bmjopen-2020-040644","volume":"10","author":"H Dambha-Miller","year":"2020","unstructured":"Dambha-Miller H, Albasri A, Hodgson S, Wilcox CR, Khan S, Islam N, Little P, Griffin SJ (2020) Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. BMJ Open 10:e040644. https:\/\/doi.org\/10.1136\/bmjopen-2020-040644","journal-title":"BMJ Open"},{"key":"2129_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/CS20201511","volume":"135","author":"MA Pedrosa","year":"2021","unstructured":"Pedrosa MA, Valenzuela R, Garrido-Gil P, Labandeira CM, Navarro G, Franco R, Labandeira-Garcia JL, Rodriguez-Perez AI (2021) Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci (Lond) 135:465\u2013481. https:\/\/doi.org\/10.1042\/CS20201511","journal-title":"Clin Sci (Lond)"},{"key":"2129_CR38","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1161\/HYPERTENSIONAHA.120.15829","volume":"76","author":"JA Chirinos","year":"2020","unstructured":"Chirinos JA, Cohen JB, Zhao L, Hanff T, Sweitzer N, Fang J, Corrales-Medina V, Anmar R, Morley M, Zamani P, Bhattacharya P, Brandimarto J, Jia Y, Basso MD, Wang Z, Ebert C, Ramirez-Valle F, Schafer PH, Seiffert D, Gordon DA, Cappola T (2020) Clinical and proteomic correlates of plasma ACE2 (angiotensin-converting enzyme 2) in human heart failure. Hypertension 76:1526\u20131536. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15829","journal-title":"Hypertension"},{"key":"2129_CR39","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryden","year":"2013","unstructured":"Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A, Funck-Brentano C, Gulba DC, Kjekshus JK, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035\u20133087. https:\/\/doi.org\/10.1093\/eurheartj\/eht108","journal-title":"Eur Heart J"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02129-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-021-02129-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02129-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T11:03:46Z","timestamp":1637147026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-021-02129-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1007\/s00109-021-02129-4","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by our local Ethics Committee for Human Studies and in accordance with the 1975 Declaration of Helsinki and subsequent amendments (Registry no. 2008\/392).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}